Leriglitazone

Summary

Leriglitazone (CHEMBL1267) is a phase-3 clinical-stage small molecule (ATC A16AX23); indicated across 3 conditions including adrenoleukodystrophy and friedreich ataxia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A16AX23
• Indications: 3 conditions
• Clinical trials: 4
• Chemistry: 372.4 Da · C19H20N2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1267
Name	Leriglitazone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	4147757
ChEBI	CHEBI:82937
ATC	A16AX23
Molecular formula	C19H20N2O4S
Molecular weight	372.4
InChIKey	OXVFDZYQLGRLCD-UHFFFAOYSA-N

SMILES: CC(C1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3)O

IUPAC name: 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

ChEBI definition: A member of the class of thiazolidenediones that is the hydroxy derivative of pioglitazone.

Other ChEBI roles (chemical / environmental): human xenobiotic metabolite.

Also known as: Hydroxypioglitazone, Leriglitazona, Leriglitazone, Min-102, MIN-102, LERIGLITAZONE

Parent form; salt/anhydrous children: CHEMBL4298170

Patent coverage: 31 distinct patent families (86 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Peroxisome proliferator-activated receptor gamma.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PPARG	6.17	EC50	680	nM	CHEMBL_ACT_19302642
PPARG	6.15	Kd	708	nM	CHEMBL_ACT_19302640
PPARG	5.92	Ki	1200	nM	CHEMBL_ACT_19302628
PPARG	5.89	EC50	1300	nM	CHEMBL_ACT_19302644
PPARG	5.68	EC50	2100	nM	CHEMBL_ACT_19302632

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
adrenoleukodystrophy	2	MONDO:0018544	MONDO:0018544
Friedreich ataxia	2	MONDO:0100339	MONDO:0100339

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	2
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05819866	PHASE3	RECRUITING	A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
NCT03231878	PHASE2/PHASE3	COMPLETED	A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
NCT03917225	PHASE2	COMPLETED	A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich’s Ataxia in Male and Female Patients
NCT04528706	PHASE2	UNKNOWN	A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).